

10/564029

IAP20 Rec'd PCT/PTO PATENT 09 JAN 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	P. Jeffrey Conn et al.	
Serial No.:	To Be Assigned	Case No.: 21463P
US Nat'l Filing Date:	January 9, 2006	
Int'l Appl'n No.	PCT/US2004/021776	
Int'l Filing Date:	07 July 2004	
For:	TREATMENT OF MOVEMENT DISORDERS WITH A METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR	

Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT January 9, 2006  
EXPRESS MAIL NO. EA00011156US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Christina Cuffe  
DATE 1-9-06

10/564029

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

IAP20 REC 3 FCIT/PTO 09 JAN 2006


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference HH (abstract of WO 2002/068417) was cited in the International Search Report for this application. A copy of the International Search Report and Written Opinion of the International Searching Authority are enclosed.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: January 9, 2006

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>   <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	To Be Assigned
				Filing Date	JAN 09 2006
				First Named Inventor	P. Jeffrey Conn et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	21463P

[illegible][illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
				Application Number	To Be Assigned
				Filing Date	January 9, 2006
				First Named Inventor	P. Jeffrey Conn et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	21463P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	H. Annoura et al., "A Novel Class of Antagonists for Metabotropic Glutamate Receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates," Biorganic & Medicinal Chemistry Letters, Vol. 6, No. 7, pp. 763-766 (1996)
	BB	P. J. Flor et al., "Postive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 4: Pharmacological and Molecular Characterization," Abstract/Neuropharmacology, 43:286 (2002)
	CC	M. J. Marino et al., "Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Basal Ganglia Motor Circuit," Abstracts/Neuropharmacology, 43:297-298 (2002)
	DD	O. Valenti et al., "Modulation of Inhibitory Transmission in the Rat Globus Pallidus by Group III Metabotropic Glutamate Receptors," Abstracts/Neuropharmacology, 43:311 (2002)
	EE	O. Valenti et al., "Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons," JPET, Vol. 313, pp. 1296-1304 (2005)
	FF	M. J. Marino et al., "Modulation of Inhibitory Transmission in the Rat Globus Pallidus by Activation of mGluR4," Ann. N.Y. Acad. Sci 1003: 435-437 (2003)
	GG	O. Valenti et al., "Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse," J. Neuroscience, Vol. 23, No. 18, pp. 7218-7226 (2003)
	HH	Patent Abstract of WO 2002/068417

Examiner Signature		Date Considered	
--------------------	--	-----------------	--